Benitec Biopharma Shakes Up Management Team

Dow Jones12-14

By Katherine Hamilton

Benitec Biopharma appointed Sophie Mukadam as its chief operating officer and named executive director Megan Boston to its chief financial officer role.

Mukadam will take the post effective Jan. 1 and will receive a base salary of $500,000 and a target annual bonus of 40% of her base salary, according to a Friday filing with the Securities and Exchange Commission.

Mukadam has been serving as Benitec's associate director of program management, starting in May 2021. Before joining the company, she worked as a regulatory consultant. She holds a bachelor's degree from the University of California, Berkeley.

Boston was appointed chief financial officer effective Jan. 1. She was also confirmed as the company's secretary. Boston will continue serving as the principal financial officer and principal accounting officer.

Boston is set to receive $415,000 in annual salary, with a target annual discretionary bonus of 40% of that salary. She has been granted nonqualified stock options to purchase 720,000 shares, according to a filing. The options were granted at an exercise price of $12.18 per share.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 13, 2024 17:41 ET (22:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491058126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 06:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491058126","market":"us","top_or_hot":-1,"title":"Benitec Biopharma Shakes Up Management Team","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Benitec Biopharma appointed Sophie Mukadam as its chief operating officer and named executive director Megan Boston to its chief financial officer role. \n</p>\n<p>\n  Mukadam will take the post effective Jan. 1 and will receive a base salary of $500,000 and a target annual bonus of 40% of her base salary, according to a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Mukadam has been serving as Benitec's associate director of program management, starting in May 2021. Before joining the company, she worked as a regulatory consultant. She holds a bachelor's degree from the University of California, Berkeley. \n</p>\n<p>\n  Boston was appointed chief financial officer effective Jan. 1. She was also confirmed as the company's secretary. Boston will continue serving as the principal financial officer and principal accounting officer. \n</p>\n<p>\n  Boston is set to receive $415,000 in annual salary, with a target annual discretionary bonus of 40% of that salary. She has been granted nonqualified stock options to purchase 720,000 shares, according to a filing. The options were granted at an exercise price of $12.18 per share. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 17:41 ET (22:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma Shakes Up Management Team</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma Shakes Up Management Team\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 06:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Katherine Hamilton \n\n\n  Benitec Biopharma appointed Sophie Mukadam as its chief operating officer and named executive director Megan Boston to its chief financial officer role. \n\n\n  Mukadam will ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4120","symbol_name":"环境与设施服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491058126","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491058126","pubTimestamp":1734129660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Benitec Biopharma appointed Sophie Mukadam as its chief operating officer and named executive director Megan Boston to its chief financial officer role.Mukadam will take the post effective Jan. 1 and will receive a base salary of $500,000 and a target annual bonus of 40% of her base salary, according to a Friday filing with the Securities and Exchange Commission.Mukadam has been serving as Benitec's associate director of program management, starting in May 2021. Before joining the company, she worked as a regulatory consultant. She holds a bachelor's degree from the University of California, Berkeley.Boston was appointed chief financial officer effective Jan. 1. She was also confirmed as the company's secretary. Boston will continue serving as the principal financial officer and principal accounting officer.Boston is set to receive $415,000 in annual salary, with a target annual discretionary bonus of 40% of that salary. She has been granted nonqualified stock options to purchase 720,0","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4120":"环境与设施服务","BK4139":"生物科技","BNTC":"Benitec Biopharma Limited","TISI":"Team Inc"},"translate_title":"Benitec Biopharma改组管理团队","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTC":1,"TISI":1},"content_text":"By Katherine Hamilton \n\n\n  Benitec Biopharma appointed Sophie Mukadam as its chief operating officer and named executive director Megan Boston to its chief financial officer role. \n\n\n  Mukadam will take the post effective Jan. 1 and will receive a base salary of $500,000 and a target annual bonus of 40% of her base salary, according to a Friday filing with the Securities and Exchange Commission. \n\n\n  Mukadam has been serving as Benitec's associate director of program management, starting in May 2021. Before joining the company, she worked as a regulatory consultant. She holds a bachelor's degree from the University of California, Berkeley. \n\n\n  Boston was appointed chief financial officer effective Jan. 1. She was also confirmed as the company's secretary. Boston will continue serving as the principal financial officer and principal accounting officer. \n\n\n  Boston is set to receive $415,000 in annual salary, with a target annual discretionary bonus of 40% of that salary. She has been granted nonqualified stock options to purchase 720,000 shares, according to a filing. The options were granted at an exercise price of $12.18 per share. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 17:41 ET (22:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491058126"}